Efficacy outcomes in preclinical gene therapy
To judge whether a gene therapy approach for Hurler syndrome (severe MPS I, MPS I-H) is worth taking forward, researchers need more than a single laboratory result. The preclinical programme evaluates efficacy across multiple layers, including biochemical markers, tissue histology, survival and simple behavioural outcomes in MPS I-H animal models.
This page explains, in accessible scientific language, how efficacy is assessed in the preclinical gene therapy studies and how the different readouts fit together to give a picture of overall benefit.
Note: These data come from preclinical studies in animal models. They do not represent results in children or adults and are not a guarantee of future clinical benefit.
From enzyme activity to whole-animal outcomes
In the preclinical MPS I-H gene therapy programme, efficacy means evidence that the treatment:
- Increases alpha-L-iduronidase activity in blood and tissues
- Reduces the build-up of harmful glycosaminoglycans (GAGs)
- Improves the structure and appearance of organs on histology
- Supports better overall health, behaviour and survival in MPS I model animals
No single measure is enough on its own. Robust efficacy assessment combines:
- Biochemical endpoints
- Histological endpoints
- Functional and behavioural endpoints
- Survival data
The more consistent the findings across these domains, the stronger the case for moving towards clinical testing.
From enzyme activity to whole-animal outcomes
In the preclinical MPS I-H gene therapy programme, efficacy means evidence that the treatment:
- Increases alpha-L-iduronidase activity in blood and tissues
- Reduces the build-up of harmful glycosaminoglycans (GAGs)
- Improves the structure and appearance of organs on histology
- Supports better overall health, behaviour and survival in MPS I model animals
No single measure is enough on its own. Robust efficacy assessment combines:
- Biochemical endpoints
- Histological endpoints
- Functional and behavioural endpoints
- Survival data
The more consistent the findings across these domains, the stronger the case for moving towards clinical testing.
Enzyme activity and GAG reduction
Biochemical markers are the earliest and most direct readout of whether gene therapy is working at a molecular level.
Alpha-L-iduronidase activity
After dosing, researchers measure:
- Enzyme activity in plasma or serum over time
- Enzyme activity in key tissues (for example liver, spleen, heart and brain) at the end of the study
Typical findings in treated MPS I-H model animals, compared with untreated disease controls, include:
- Detectable alpha-L-iduronidase activity where there was previously little or none
- A dose-related increase in enzyme activity in blood and tissues
- Levels that move towards, or into, the range seen in healthy animals in some dose groups
GAG and biomarker levels
Because Hurler syndrome is driven by GAG accumulation, a central efficacy goal is to reduce:
- Dermatan sulfate and heparan sulfate levels, or related GAG biomarkers, in blood and urine
- Storage markers in specific organs at necropsy
In the preclinical programme:
- Treated animals show substantial reductions in circulating and urinary GAG markers compared with untreated MPS I controls
- Reductions are more pronounced at higher dose levels, within the studied range
- In some tissues, GAG levels approach those seen in healthy animals
These biochemical changes show that gene therapy is not only producing enzyme but also affecting its downstream substrate.
Organ-level evidence of reduced storage
To move from biochemistry to organ health, the programme uses detailed tissue analysis.
Lysosomal storage
At the end of the study, organs such as liver, spleen, heart, lung, brain and bone are examined under the microscope. Pathologists look for:
- Degree of lysosomal vacuolation in cells, a hallmark of storage
- Presence or reduction of characteristic foamy or enlarged cells in different tissues
Compared with untreated MPS I animals:
- Treated animals show less extensive vacuolation in many organs
- In some tissues, the architecture appears much closer to that of wild-type controls
- Improvements correlate broadly with biochemical normalisation
Organ-specific patterns
Different organs respond differently, reflecting their biology and accessibility:
- Liver and spleen: Often show marked storage reduction, consistent with high exposure to systemic enzyme
- Heart and great vessels: May show improved valve and vascular pathology, though some residual changes can remain
- Bone and cartilage: Can be more resistant, with variable improvements due to their avascular nature
These patterns align with known limitations of current therapies and highlight where gene therapy may add value.
Life span and clinical condition in treated animals
Beyond laboratory tests and histology, survival and overall condition provide important real-world signals in animal models.
Clinical condition and growth
Researchers also track:
- Body weight and growth trajectories
- Simple clinical observation scores (for example activity level, grooming, posture)
Treated animals often:
- Gain more weight and follow a more normal growth curve than untreated MPS I animals
- Show fewer signs of poor condition or distress in observational scoring
Survival
In many MPS I models, untreated animals:
- Have shortened survival compared with wild-type animals
- Develop progressive multisystem disease that reduces lifespan
In the gene therapy studies:
- Treated MPS I animals commonly show extended survival compared with untreated disease controls, particularly at efficacious doses
- Survival curves move closer to those of healthy animals in some cohorts, within the limitations of study duration
These findings suggest that biochemical and histological improvements translate into better whole-body health in the model.
Simple measures of movement and activity
While mouse behavioural testing is necessarily limited and not directly equivalent to human neurocognitive assessment, it can add useful information.
Depending on the specific study, assessments may include:
- Basic locomotor and coordination tasks, such as simple activity or movement tests
- General behaviour observations, such as spontaneous activity in the home cage and response to handling
Treated animals typically:
- Perform more like wild-type animals on simple movement or activity measures
- Show fewer gross motor abnormalities than untreated disease controls
These findings suggest that improved enzyme activity and reduced storage may have functional consequences, although they cannot be directly equated to human neurocognitive outcomes.
Unresolved problems with current standard of care
HSCT and ERT have transformed the outlook for many children with MPS I-H, but major gaps remain.
For clinicians, researchers and families
For clinicians and researchers
Efficacy outcomes should be viewed in relation to:
- The dose levels and vectors used
- The age at treatment and follow-up duration
- The comparators, including untreated disease controls and wild-type animals
Points to consider:
- Do biochemical and histological outcomes move towards normal, and in how many organs?
- Are survival and functional improvements meaningful compared with known natural history in the model?
- Are there any dose levels where toxicity begins to counterbalance efficacy?
These questions help in designing or evaluating early-phase clinical trials.
For families and adults
Key messages in plain language:
- In MPS I mice, gene therapy leads to more enzyme, less storage, healthier organs, and often longer, healthier lives than in untreated mice.
- This is promising, but mice are not people and we cannot assume the same results will occur in children or adults.
- Efficacy data from animals are an important step, but only clinical trials can show whether a treatment is safe and effective in humans.
Building a multi-layered picture of benefit
The strength of the preclinical package lies in the concordance of findings:
- Biochemical data show increased enzyme and reduced GAGs
- Histology shows less lysosomal storage in multiple organs
- Survival, growth and behavioural data point to better overall health
When improvements are seen consistently across these domains, especially in a dose-related pattern, it supports the conclusion that:
- The gene therapy is biologically active
- The effects are clinically relevant in the context of an animal model
This integrated approach is essential for regulators, clinicians and families to judge whether moving into human trials is justified.
What these measures do not show
Even strong preclinical efficacy has limits:
- Animal behavioural tests do not fully capture human neurocognition, schooling or quality of life
- Study follow-up spans months, while children with Hurler syndrome need treatment effects to last years to decades
- The controlled environment of a laboratory does not reflect the complexity of human comorbidities and healthcare systems
- Some organ systems (especially bone and CNS) may still be only partly corrected in models, echoing challenges seen with existing therapies
Recognising these limitations helps manage expectations and design realistic clinical trials.
Key points about efficacy outcomes
- Efficacy in the MPS I-H gene therapy programme is assessed via biochemical markers, histology, survival and basic behavioural outcomes.
- Treated animals show increased alpha-L-iduronidase activity, reduced GAG storage and improved organ histology compared with untreated MPS I animals.
- Survival, growth and general condition are better in treated animals, suggesting that laboratory improvements translate into whole-animal benefit.
- Behavioural tests provide supportive evidence of functional improvement but cannot be directly equated to human neurocognitive outcomes.
- These preclinical efficacy data strongly support continued development, but they do not replace the need for careful clinical trials in people.
What to read next
Preclinical gene therapy programme
Plain language summary of the overall programme
Animal models and study design
Mouse model, dosing strategy and follow-up
Rationale for gene therapy
Why systemic gene therapy is being explored in MPS I-H
Scientific background
Molecular and cellular mechanisms of Hurler syndrome
Current standard of care
HSCT, ERT and multidisciplinary management
Unmet need
Residual morbidity after existing treatments